Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Caspofungin dose-escalation pharmacokinetic study in febrile neutropenic children aged 3 to 24 months
2014-005030-54Phase 2
- Sponsor
- Merck & Co.
- Start
- Feb 2015
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of caspofungin in mycoses (2 arms), sponsored by Merck & Co. Primary endpoint: Caspofungin pharmacokinetic profile at 50 mg/m2/day.
02
Drugs
caspofungin
03
Conditions
mycoses
Beyond the preview
Go deeper on 2014-005030-54.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005030-54.